Extrahepatic disorders of HCV infection: A distinct entity of B-cell neoplasia?

International Journal of Oncology

Volumn 36, Issue 6, 2010, Pages 1331-1340

  Libra, Massimo ^a   Polesel, Jerry ^b   Russo, Alessia Erika ^a   De Re, Vallì ^b   Cinà, Diana ^c   Serraino, Diego ^b   Nicoletti, Ferdinando ^a   Spandidos, Demetrios A ^d   Stivala, Franca ^a   Talamini, Renato ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c GARIBALDI HOSPITAL   (Italy)

^d UNIVERSITY OF CRETE   (Greece)

Author keywords

Casecontrol studies; Gene alterations; Hepatitis C virus; Non Hodgkin's lymphoma; VDJ rearrangement

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; PEGINTERFERON ALPHA; RIBAVIRIN; RITUXIMAB; VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; B CELL LYMPHOMA; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG EFFICACY; GENETIC DISORDER; GENOTYPE; HELICOBACTER INFECTION; HEPATITIS C; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

HEPATITIS C; HUMANS; LYMPHOMA, NON-HODGKIN; PREVALENCE;

EID: 77951586549     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000618     Document Type: Article

References (99)

1. Pagano JS: Viruses and lymphomas. N Engl J Med 347: 78-79, 2002.
2. Dolcetti R and Masucci MG: Epstein-Barr virus: induction and control of cell transformation. J Cell Physiol 196: 207-218, 2003. (Pubitemid 36775867)
3. Aboulafia DM, Pantanowitz L and Dezube BJ: AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. AIDS Read 14: 605-617, 2004. (Pubitemid 40104491)
4. Carbone A: Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol 4: 22-29, 2003.
5. Mazzaro C, Zagonel V, Monfardini S, et al: Hepatitis C virus and non-Hodgkin's lymphomas. Br J Haematol 94: 544-550, 1996.
6. Mele A, Pulsoni A, Bianco E, et al: Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102: 996-999, 2003. (Pubitemid 36917795)
7. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, Qian DG, Velankar M, Nathwani BN and Fong TL: Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 127: 423-428, 1997. (Pubitemid 27400904)
8. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K and Mueller NE: Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 95: 745-752, 2004. (Pubitemid 39335095)
9. Negri E, Little D, Boiocchi M, La Vecchia C and Franceschi S: B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 111: 1-8, 2004. (Pubitemid 38859276)
10. Talamini R, Montella M, Crovatto M, Dal Maso L, Crispo A, Negri E, Spina M, Pinto A, Carbone A and Franceschi S: Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 110: 380-385, 2004. (Pubitemid 38649889)
11. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M and Levy S: The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98: 3745-3749, 2001.
12. Dal Maso L and Franceschi S: Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 15: 2078-2085, 2006. (Pubitemid 44877029)
13. Anonymous: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage-the non-Hodgkin's lymphoma pathologic classification project. Cancer 49: 2112-2135, 1982.
14. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994. (Pubitemid 24273002)
15. Jaffe ES, Harris NL, Stein H and Vardiman JW: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, 2001.
16. Rothman KJ, Greenland S and Lash TL: Modern Epidemiology. 3rd edition. Lippincot Williams & Wilkins, Philadelphia, PA, 2008.
17. Silvestri F, Barillari G, Fanin R, Pipan C, Falasca E, Salmaso F, Zaja F, Infanti L, Patriarca F, Botta GA and Baccarani M: The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. Leukemia 11: 2157-2161, 1997. (Pubitemid 28043704)
18. Maio G, D'Argenio P and Stroffolini T: Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J Hepatol 33: 116-120, 2000. (Pubitemid 30418942)
19. Osella AR, Sonzogni L, Cavallini A, Foti L, Guerra V, Di Leo A, Mondelli MU, Misciagna G and Silini EM: Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol 37: 2371-2372, 1999. (Pubitemid 29277814)
20. Guadagnino V, Stroffolini T and Rapicetta M: Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 26: 1006-1111, 1997. (Pubitemid 27413671)
21. Fornasieri A, Bernasconi P, Ribero ML, Sinico RA, Fasola M, Zhou J, Portera G, Tagger A, Gibelli A and D'Amico G: Hepatitis C virus (HCV) in lymphocyte subsets and in B lymphocytes expressing rheumatoid factor cross-reacting idiotype in type II mixed cryoglobulinaemia. Clin Exp Immunol 122: 400-403, 2000. (Pubitemid 32002198)
22. Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, Yen TS, Lindsay KL, Levine AM and Lai MM: Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 77: 2134-2146, 2003.
23. De Vita S, Sansonno D, Dolcetti R, Ferraccioli G, Carbone A, Cornacchiulo V, Santini G, Crovatto M, Gloghini A, Dammacco F and Boiocchi M: Hepatitis C virus within a malignant lymphoma lesion in the course of type II mixed cryoglobulinemia. Blood 86: 1887-1892, 1995.
24. Sansonno D, De Vita S, Cornacchiulo V, Carbone A, Boiocchi M and Dammacco F: Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation. Blood 88: 4638-4645, 1996. (Pubitemid 26419147)
25. De Vita S, De Re V and Sansonno D: Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology 31: 182-189, 2000. (Pubitemid 30033705)
26. De Vita S, De Re V, Sansonno D, Gloghini A, Gasparotto D, Libra M, Sacco S, Carbone A, Ferraccioli G and Boiocchi M: Lack of HCV infection in malignant cells refutes the hypothesis of a direct transforming action of the virus in the pathogenesis of HCV-associated B-cell NHLs. Tumori 88: 400-406, 2002. (Pubitemid 35356108)
27. De Re V, De Vita S, Marzotto A, Gloghini A, Pivetta B, Gasparotto D, Cannizzaro R, Carbone A and Boiocchi M: Premalignant and malignant lymphoproliferations in an HCVinfected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. Int J Cancer 87: 211-216, 2000. (Pubitemid 30434347)
28. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR and Efremov DG: Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91: 2433-2442, 1998. (Pubitemid 28155518)
29. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A and Boiocchi M: Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96: 3578-3584, 2000.
30. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, Cuoghi A and Torelli G: Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol 159: 253-261, 2001. (Pubitemid 33704210)
31. Gasparotto D, De Re V and Boiocchi M: Hepatitis C virus, B-cell proliferation and lymphomas. Leuk Lymphoma 43: 747-751, 2002.
32. B¢rretzen M, Randen I, Zdársky E, F¢rre O, Natvig JB and Thompson KM: Control of autoantibody affinity by selection against amino acid replacements in the complementarity-determining regions. Proc Natl Acad Sci USA 91: 12917-12921, 1994.
33. Chan CH, Hadlock KG, Foung SK and Levy S: V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97: 1023-1026, 2001.
34. Engel P and Tedder TF: New CD from the B cell section of the Fifth International Workshop on Human Leukocyte Differentiation Antigens. Leuk Lymphoma 13: 61-64, 1994. (Pubitemid 24158945)
35. Petracca R, Falugi F and Galli G: Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol 74: 4824-4830, 2000. (Pubitemid 30237910)
36. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G and Abrignani S: Binding of hepatitis C virus to CD81. Science 282: 938-941, 1998.
37. Flint M, Quinn ER and Levy S: In search of hepatitis C virus receptor(s). Clin Liver Dis 5: 873-893, 2001.
38. Flint M, Thomas JM, Maidens CM, Shotton C, Levy S, Barclay WS and McKeating JA: Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 73: 6782-6790, 1999. (Pubitemid 29327861)
39. Yagnik AT, Lahm A, Meola A, Roccasecca RM, Ercole BB, Nicosia A and Tramontano A: A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40: 355-366, 2000. (Pubitemid 30624444)
40. Garson JA, Whitby K, Watkins P and Morgan AJ: Lack of susceptibility of the cottontop tamarin to hepatitis C infection. J Med Virol 52: 286-288, 1997. (Pubitemid 27305748)
41. Meola A, Sbardellati A and Bruni Ercole B: Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J Virol 74: 5933-5938, 2000. (Pubitemid 30412962)
42. Bradbury LE, Kansas GS, Levy S, Evans RL and Tedder TF: The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 149: 2841-2850, 1992.
43. Carter RH and Fearon DT: CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256: 105-107, 1992.
44. Andus T, Bauer J and Gerok W: Effects of cytokines on the liver. Hepatology 13: 364-375, 1991.
45. Dinarello CA: Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Curr Opin Pharmacol 4: 378-385, 2004.
46. Cominelli F and Pizarro TT: Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment Pharmacol Ther 2: 49-53, 1996. (Pubitemid 26341295)
47. Arend WP: Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 30: 1-6, 2001. (Pubitemid 32467129)
48. Nicoletti F, Patti F, Di Marco R, Zaccone P, Nicoletti A, Meroni P and Reggio A: Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment. Cytokine 8: 395-400, 1996. (Pubitemid 126333711)
49. De Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA, Remarque EJ, Burgmans AC, Kalkers NF, Polman CH and Westendorp RG: Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 126: 172-179, 2002.
50. Chang DM: Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus. Immunol Invest 26: 649-659, 1997. (Pubitemid 27499968)
51. Libra M, Mangano K and Anzaldi M: Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep 15: 1305-1308, 2006.
52. Furst DE: Anakinra: review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26: 1960-1975, 2004.
53. Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA and Mazzarino MC: Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biol Ther 4: 1192-1194, 2005.
54. Küppers R, Klein U, Hansmann ML and Rajewsky K: Cellular origin of human B-cell lymphomas. N Engl J Med 341: 1520-1529, 1999. (Pubitemid 29526356)
55. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Küppers R and Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412: 341-346, 2001. (Pubitemid 32691848)
56. Gaidano G, Pasqualucci L, Capello D, Berra E, Deambrogi C, Rossi D, Maria Larocca L, Gloghini A, Carbone A and Dalla-Favera R: Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. Blood 102: 1833-1841, 2003.
57. Montesinos-Rongen M, van Roost D, Schaller C, Wiestler OD and Deckert M: Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 103: 1869-1875, 2004.
58. Libra M, Capello D, Gloghini A, Laura P, Berra E, Cerri M, Gasparotto D, Franca S, De Re V, Gaidano G and Carbone A: Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol 206: 87-91, 2005. (Pubitemid 40613438)
59. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY and Lai MM: Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 101: 4262-4267, 2004. (Pubitemid 38405917)
60. Zignego AL, Giannelli F, Marrocchi ME, Mazzocca A, Ferri C, Giannini C, Monti M, Caini P, Villa GL, Laffi G and Gentilini P: T(14;18) translocation in chronic hepatitis C virus infection. Hepatology 31: 474-479, 2000. (Pubitemid 30078615)
61. Kitay-Cohen Y, Amiel A, Hilzenrat N, Buskila D, Ashur Y, Fejgin M, Gaber E, Safadi R, Tur-Kaspa R and Lishner M: Bcl-2 rearrangement in patients with chronic hepatitis C associated with essential mixed cryoglobulinemia type II. Blood 96: 2910-2912, 2000.
62. Zignego AL, Ferri C, Giannelli F, Giannini C, Caini P, Monti M, Marrocchi ME, Di Pietro E, La Villa G, Laffi G and Gentilini P: Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 137: 571-580, 2002.
63. Libra M, De Re V, Gloghini A, Gasparotto D, Gragnani L, Navolanic PM, De Vita S, Mazzarino MC, Zignego AL, Carbone A and Boiocchi M: Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica 89: 873-874, 2004. (Pubitemid 38981354)
64. Libra M, Gloghini A, Navolanic PM, Zignego AL, De Re V and Carbone A: JH6 gene usage among HCV-associated MALT lymphomas harboring t(14;18) translocation. J Immunol 174: 3839, 2005.
65. Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL and Carbone A: Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol 49: 170-174, 2008.
66. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, De Boni M and Isaacson PG: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575-577, 1993. (Pubitemid 23259233)
67. Mazzaro C, Franzin F, Tulissi P, Pussini E, Crovatto M, Carniello GS, Efremov DG, Burrone O, Santini G and Pozzato G: Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 77: 2604-2613, 1996. (Pubitemid 126497594)
68. Zuckerman E, Zuckerman T, Sahar D, Streichman S, Attias D, Sabo E, Yeshurun D and Rowe JM: The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangement in patients with chronic hepatitis C virus infection. Blood 97: 1555-1559, 2001. (Pubitemid 32217215)
69. Giannelli F, Moscarella S and Giannini C: Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 102: 1196-1201, 2003. (Pubitemid 36988022)
70. Hermine O, Lefrère F and Bronowicki JP: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 347: 89-94, 2002. (Pubitemid 34753478)
71. Vallisa D, Bernuzzi P and Arcaini L: Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 23: 468-473, 2005. (Pubitemid 46224223)
72. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G and Rizzi R: Natural interferon-α versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long term, randomized, controlled study. Blood 84: 3336-3343, 1994. (Pubitemid 24352895)
73. Tavoni A, Mosca M, Ferri C, Moriconi L, La Civita L, Lombardini F and Bombardieri S: Guidelines for the management of essential mixed cryoglobulinemia. Clin Exp Rheumatol 13: S191-S195, 1995. (Pubitemid 26127959)
74. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A and Baccarani M: Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 84: 1157-1158, 1999. (Pubitemid 30016593)
75. Grillo-Lopez AJ, Hedrick E, Rashford M and Benyunes M: Rituximab: ongoing and future clinical development. Semin Oncol 29: 105-112, 2002. (Pubitemid 34173032)
76. Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G and Baccarani M: Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 46: 2252-2254, 2002. (Pubitemid 36857853)
77. Foxton MR, Knight L, Knisely AS, Mufti GJ, O'Grady J, Muiesan P and Norris S: Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. Liver Transpl 11: 839-842, 2005. (Pubitemid 40975587)
78. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W and Gross WL: Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 62: 1230-1233, 2003. (Pubitemid 37500635)
79. Sansonno D, De Re V, Lauletta G, Tucci FA, Baiocchi M and Dammacco F: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 101: 3818-3826, 2003. (Pubitemid 36857852)
80. Zaja F, De Vita S, Mazzero C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R and Ferraccioli G: Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827-3834, 2003. (Pubitemid 36857853)
81. Ramos-Casals M, López-Guillermo A, Brito-Zerón P, Cervera R and Font J: SS-HCV Study Group. Treatment of B-cell lymphoma with rituximab in two patients with Sjögren's syndrome associated with hepatitis C virus infection. Lupus 13: 969-971, 2004.
82. Roccatello D, Baldovino S and Rossi D: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 19: 3054-3061, 2004. (Pubitemid 40057628)
83. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G and De Vita S: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Reumatology (Oxford) 45: 842-846, 2006. (Pubitemid 43985372)
84. Roccatello D, Baldovino S and Rossi D: Rituximab as a therapeutic tool in severe mixed cryoglobulinaemia. Clin Rev Allergy Immunol 34: 111-117, 2008.
85. Cervetti G, Mechelli S, Riccioni R, Galimberti S, Caracciolo F and Petrini M: High efficacy of Rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin Exp Rheumatol 23: 877-880, 2005. (Pubitemid 43040518)
86. Guida M, D'Elia G, Benvestito S, Casamassima A, Micelli G, Quaranta M, Moschetta R, De Lena M and Lorusso V: Hepatitis C virus infection in patients with B-cell lymphoproliferative disorders. Leukemia 16: 2162-2163, 2002. (Pubitemid 35203465)
87. Montella M, Crispo A, Frigeri F, Ronga D, Tridente V, De Marco M, Fabbrocini G, Spada O, Mettivier V and Tamburini M: HCV and tumors correlated with immune system: a case-control study in an area of hyperendemicity. Leuk Res 25: 775-781, 2001. (Pubitemid 32727980)
88. Vallisa D, Bertè R, Rocca A, Civardi G, Giangregorio F, Ferrari B, Sbolli G and Cavanna L: Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course. Am J Med 106: 556-560, 1999. (Pubitemid 29231107)
89. De Vita S, Zagonel V, Russo A, Rupolo M, Cannizzaro R, Chiara G, Boiocchi M, Carbone A and Franceschi S: Hepatitis C virus, non-Hodgkin's lymphomas and hepatocellular carcinoma. Br J Cancer 77: 2032-2035, 1998. (Pubitemid 28254653)
90. Musto P, Dell'Olio M, Carotenuto M, Mangia A and Andriulli A: Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? Blood 88: 752-754, 1996.
91. De Renzo A, Persico E, De Marino F, Di Giacomo Russo G, Notaro R, Di Grazia C, Picardi M, Santoro L, Torella R, Rotoli B and Persico M: High prevalence of hepatitis G virus infection in Hodgkin's disease and B-cell lymphoproliferative disorders: absence of correlation with hepatitis C virus infection. Haematologica 87: 714-718, 2002. (Pubitemid 34787142)
92. Pioltelli P, Gargantini L, Cassi E, Santoleri L, Bellati G, Magliano EM and Morra E: Hepatitis C virus in non-Hodgkin's lymphoma. A reappraisal after a prospective case-control study of 300 patients. Lombart Study Group of HCV-Lymphoma. Am J Hematol 64: 95-100, 2000. (Pubitemid 30324465)
93. Luppi M, Longo G, Ferrari MG, Barozzi P, Marasca R, Morselli M, Valenti C, Mascia T, Vandelli L, Vallisa D, Cavanna L and Torelli G: Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol 9: 495-498, 1998. (Pubitemid 28270636)
94. Catassi C, Fabiani E, Coppa GV, et al: High prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma at the onset. Preliminary results of an Italian multicenter study. Recenti Prog Med 89: 63-67, 1998.
95. Pivetti S, Novarino A, Merico F, Bertero MT, Brunetto MR, Bonino F and Caligaris-Cappio F: High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders. Br J Haematol 95: 204-211, 1996. (Pubitemid 26340253)
96. Pioltelli P, Zehender G, Monti G, Monteverde A and Galli M: HCV and non-Hodgkin lymphoma. Lancet 347: 624-625, 1996.
97. Musolino C, Campo S, Pollicino T, Squadrito G, Spatari G and Raimondo G: Evaluation of hepatitis B and C virus infections in patients with non-Hodgkin's lymphoma and without liver disease. Haematologica 81: 162-164, 1996.
98. Andriani A, Bibas M and Di Giacomo C: Liver involvement during HCV infection in chronic lymphoproliferative diseases. Haematologica 81: 589-590, 1996.
99. Ferri C, La Civita L, Caracciolo F, Bellesi G and Zignego AL: Hepatitis C virus and lymphoproliferative disorders. Blood 88: 4730-4731, 1996.